[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340188-105":59,"doc-detail-340188-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","epigenetic-reader-zmynd11-noncanonical-function-restricts-hnrnpa1-mediated-stress-granule-formation-and-oncogenic-activity-signal-transduction-and-targeted-therapy","Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity - Signal Transduction and Targeted Therapy","","Epigenetic readers regulate gene expression, influence cancer prognosis, and can serve as therapeutic targets. This work focuses on zinc finger MYND-type containing 11 (ZMYND11), a known reader of H3.3K36me3, and investigates its underexplored cancer functions. ZMYND11 downregulation is common in multiple cancers and correlates with worse outcomes in prostate cancer. ZMYND11 depletion enhances tumor cell growth, migration, invasion, and metastasis. Mechanistically, ZMYND11 recognizes arginine-194-methylated HNRNPA1 via its MYND domain, retaining HNRNPA1 in the nucleus, blocking cytoplasmic stress granules, and restraining PKM2-driven aggressive phenotypes. PRMT5 inhibition disrupts the interaction and renders low-ZMYND11 tumors sensitive, suggesting biomarkers and therapeutic avenues.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/epigenetic-reader-zmynd11-noncanonical-function-restricts-hnrnpa1-mediated-stress-granule-formation-and-oncogenic-activity-signal-transduction-and-targeted-therapy/340188/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/epigenetic-reader-zmynd11-noncanonical-function-restricts-hnrnpa1-mediated-stress-granule-formation-and-oncogenic-activity-signal-transduction-and-targeted-therapy/340188.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does ZMYND11 play in cancer according to the study?","Question",{"text":112,"@type":113},"ZMYND11 acts as a tumor suppressor. Its downregulation correlates with poorer outcomes, and ZMYND11 loss increases tumor growth, migration, invasion, and metastasis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ZMYND11 regulate stress granule formation?",{"text":117,"@type":113},"ZMYND11 recognizes arginine-194-methylated HNRNPA1 through its MYND domain, retaining HNRNPA1 in the nucleus and preventing cytoplasmic stress granule formation.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is PRMT5 inhibition relevant to tumors with low ZMYND11 expression?",{"text":121,"@type":113},"PRMT5 inhibition disrupts the ZMYND11-HNRNPA1 interaction by blocking arginine methylation. Tumors with low ZMYND11 expression show increased sensitivity to PRMT5 inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340188,1790705206,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nEpigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity  \nCheng Lian 1, Chunyi Zhang1, Pan Tian 1, Qilong Tan2, Yu Wei3, Zixian Wang 1, Qin Zhang4, Qixiang Zhang 1, Mengjie Zhong 1, Li-Quan Zhou5, Xisong Ke6, Huabing Zhang7, Yao Zhu3, Zhenfei Li2, Jingdong Cheng 8 and Gong-Hong Wei 1,9 ✉  \n\n|  | Epigenetic readers frequently affect gene regulation, correlate with disease prognosis, and hold signiﬁcant potential as therapeutic targets for cancer. Zinc ﬁnger MYND-type containing 11 (ZMYND11) is notably recognized for reading the epigenetic marker H3.3K36me3; however, its broader functions and mechanisms of action in cancer remain underexplored. Here, we report that ZMYND11 downregulation is prevalent across various cancers and profoundly correlates with poorer outcomes in prostate cancer patients. Depletion of ZMYND11 promotes tumor cell growth, migration, and invasion in vitro, as well as tumor formation and metastasis in vivo. Mechanistically, we discover that ZMYND11 exhibits tumor suppressive roles by recognizing arginine-194-methylated HNRNPA1 dependent on its MYND domain, thereby retaining HNRNPA1 in the nucleus and preventing the formation of stress granules in the cytoplasm. Furthermore, ZMYND11 counteracts the HNRNPA1-driven increase in the PKM2/PKM1 ratio, thus mitigating the aggressive tumor phenotype promoted by PKM2 . Remarkably, ZMYND11 recognition of HNRNPA1 can be disrupted by pharmaceutical inhibition of the arginine methyltransferase PRMT5 . Tumors with low ZMYND11 expression show sensitivity to PRMT5 inhibitors. Taken together, our ﬁndings uncover a previously unexplored noncanonical role of ZMYND11 as a nonhistone methylation reader and underscore the critical importance of arginine methylation in the ZMYND11-HNRNPA1 interaction for |  |  |\n| --- | --- | --- | --- |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n|  |  |  |  |\n| restraining tumor progression, thereby proposing novel therapeutic |  | targets and potential biomarkers for cancer treatment. |  |\n|  | Signal Transduction and Targeted Therapy (2024)9:258 | ; [https://doi.org/10.1038/s41392-024-01961-7](https://doi.org/10.1038/s41392-024-01961-7) |  |\n|  |  |  |  |\n\nINTRODUCTION  \nCancer is a complex disease characterized by the intricate interactions between oncogenes and tumor suppressors, which are pivotal in tumor initiation, progression, and therapeutic response.1 Central to these processes are epigenetic modiﬁcations that regulate gene expression and maintain cellular identity. Aberrant epigenetic modiﬁcations, leading to dysregulation of theepigenome, have been strongly implicated in the development and progression of cancer. This dysregulation is orchestrated through a complex interplay among epigenetic “readers,” “writers,” and“erasers,” which collectively modulate chromatin landscape and gene expression.2 ZMYND11 (also known as BS69) is a notable epigenetic reader that selectively recognizes the trimethylation oflysine 36 on histone H3.3 (H3.3K36me3) through its PHD-bromoPWWP (PBP) domain. Mutations and dysfunctions of ZMYND11 have been frequently implicated in various diseases, including cancer.3–6  \nH3.3K36me3 is associated with active transcription enriched within gene bodies,7,8 with the H3.3 histone variant peaking in active chromatin regions.9 Interestingly, evidence has emerged that ZMYND11 primarily suppresses gene expression by modulating RNA polymerase II (Pol II) during the elongation phase of transcription.4–6 Furthermore, the histone-reading domain PBP is located at the N-terminus of ZMYND11, whereas the MYND domain at its C-terminus is primarily linked with the transcriptional repression of downstream oncogene","cbCaiedqIy8MqDmx","https://ap.wps.com/l/cbCaiedqIy8MqDmx","pdf",13748486,22,"English","# Introduction\n## Epigenetic readers and cancer progression\n## ZMYND11 as an H3.3K36me3 reader and possible non-canonical roles\n# Mechanistic findings and therapeutic implications","[{\"question\":\"What role does ZMYND11 play in cancer according to the study?\",\"answer\":\"ZMYND11 acts as a tumor suppressor. Its downregulation correlates with poorer outcomes, and ZMYND11 loss increases tumor growth, migration, invasion, and metastasis.\"},{\"question\":\"How does ZMYND11 regulate stress granule formation?\",\"answer\":\"ZMYND11 recognizes arginine-194-methylated HNRNPA1 through its MYND domain, retaining HNRNPA1 in the nucleus and preventing cytoplasmic stress granule formation.\"},{\"question\":\"Why is PRMT5 inhibition relevant to tumors with low ZMYND11 expression?\",\"answer\":\"PRMT5 inhibition disrupts the ZMYND11-HNRNPA1 interaction by blocking arginine methylation. Tumors with low ZMYND11 expression show increased sensitivity to PRMT5 inhibitors.\"}]","Epigenetic reader ZMYND11 noncanonical function restricts HNRNPA1-mediated stress granule formation and oncogenic activity - Signal Transduction and Targeted Therapy | PDF",1790034795,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17f9e4c9e5388cb947cf6ed3e9757a5b.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e5a2c0c4faf8bc6007300347cba1227c.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb53fd282c03551dc27a31fd59fc0b08.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afe115b0c81178498d2eaf259f5c9214.webp",980,1301]